Categories: "Medical and Research Devices"
Reference #: 2014-016
An analytical method of determining stereoisomeric excess and/or concentration and/or absolute configuration of chiral compounds in a sample of chiral analytes that can exist in stereoisomeric (enantiomeric or diasteromeric) forms using stereodynamic ligand and metal complexes.
- Evaluate high-throughput reactions whose desired product is chiral;
- Determine the stereoisomeric excess of the desired product, thus indicating the stereoselectivity of the reaction
- Determine the concentration of the total product and/or the desired isomer, thus indicating the overall or individual yield of the reaction
- High-throughput screening of chiral compounds to sense enantiomer presence, concentration and configuration Optimization of reaction parameters, allowing the development, amplification and modification of asymmetric catalysts for instance
- Enantiopurity assessment of compound samples.
- Provides for fast concentration and stereoisomeric excess
- High-throughput method accelerates the discovery progress
- Inexpensive way of sensing chirality in a large variety of chiral compounds
- Minimizes waste production
Entantioselective synthesis and analysis is central to drug development and material science in addition to
other burgeoning areas of research. The importance of chiral compounds in the pharmaceutical industry in
particular has fueled the development of asymmetric catalysts and reaction strategies. Current optimization
methods however do not efficiently probe the concentration and enantiomeric composition of chiral
compound samples to maximize reaction potential.
In the present invention Georgetown University researchers have used highly modular, chirally flexible
ligands known as “tropos ligands” as circular dichromism probes for fast concentration/configuration
analysis of chiral samples, in doing so they avoid the time consuming derivatization and purification steps
required in conventional analysis. A sample potentially containing the chiral analyte is contacted with the
stereodynamic ligand and the metal ligand and a stereodynamic metal complex is formed. When analyte is
present, the analyte coordinates to the metal center and initiates a chiral induction process and a
spectroscopic signal change. The chiral information contained in the analyte stabilizes a distinct
conformation or configuration of the stereodynamic metal complex, which can be correlated to the
analyte’s stereoisomeric excess, and a change in the spectroscopic signal can be correlated to the analyte
STAGE OF DEVELOPMENT
Reduced to practice
Published U.S. Patent Application No. 20160011156 A1